Compare Icl Group Ltd (ICL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs State Street SPDR S&P Biotech ETF — how do they compare? Icl Group Ltd trades at $5.48 (market cap $6.94B), while State Street SPDR S&P Biotech ETF trades at $159.48. The key difference: Icl Group Ltd pays a 3.86% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Icl Group Ltd nearer its low. Which is the better fit depends on your goals.
| ICL | XBI | |
|---|---|---|
Market Cap | $6.94B | — |
Sector | Basic Materials | Broad Market / Factor |
52-Week High | $6.84 | $164.28 |
52-Week Low | $4.80 | $86.92 |
Enterprise Value | $9.58B | — |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.455, up 2.15% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.12 per share, beating estimates, and announced a cost-transformation program. Revenue for 2025 was $7.15 billion, with a net income margin of 3.95%. The stock has a P/E ratio of 22.25 and an EV/EBITDA of 7.02.
Outlook is mixed; earnings beats and operational improvements support upside, but analyst consensus is entirely Hold, reflecting valuation concerns. Key risks include raw material cost volatility and foreign exchange headwinds. The stock offers a dividend yield but faces margin pressure from declining profitability trends.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
